GSK plc (NYSE:GSK) on Wednesday announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years. The update includes ...

GSK is redesigning pharmaceutical research around AI, from data infrastructure to autonomous scientific agents. Its platforms ...

(Reuters) - Drugmaker GSK said Wednesday it would invest $30 billion in U.S. research and development and supply chain infrastructure over five years, after U.S. President Donald Trump arrived in ...

GSK already has a strong presence in respiratory disease and immunology, two of its core therapeutic areas. The pharmaceutical giant is now teaming up with Flagship Pioneering in an alliance intended ...

Tell us about the work you are leading at GSK. GSK has three main R&D focuses: oncology, respiratory and immunology, and infectious diseases. I’m in the vaccines and infectious disease group, which ...

No articles found. GlaxoSmithKline R&D China did not contribute to any primary research papers from Nature Index journals in the current 12 month window. The following affiliated institutions are ...

GSK (LSE:GSK) and Alector have discontinued their phase 2 trial of an Alzheimer's drug candidate after the study did not meet efficacy goals. The decision effectively ends a high profile collaboration ...

(Alliance News) - Drugs firm GSK PLC is axing up to around 350 research and development jobs across the US and UK as part of an ongoing overhaul of the division. It is understood around 50 UK jobs so ...

When BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some financial analysts said the buyout amounted to an out-of-court settlement of ...